{"id":969338,"date":"2026-06-02T07:57:07","date_gmt":"2026-06-02T11:57:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/"},"modified":"2026-06-02T07:57:07","modified_gmt":"2026-06-02T11:57:07","slug":"picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/","title":{"rendered":"Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2014 Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures \u2014\u00a0<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>\u2014 Advancing second-generation Emperor TAH development toward a fully implantable system \u2014<\/em>\n      <\/p>\n<p>TUCSON, Ariz., June  02, 2026  (GLOBE NEWSWIRE) &#8212; Picard Medical, Inc. (NYSE American: PMI) (the \u201cCompany\u201d or \u201cPicard Medical\u201d), parent company of SynCardia Systems LLC, maker of the world\u2019s first and only total artificial heart approved by both the U.S. FDA and Health Canada, today announced the successful completion of an acute in vivo implant study series using the Company\u2019s next-generation Emperor Total Artificial Heart (\u201cEmperor TAH\u201d or \u201cEmperor\u201d) Platform at the University of Arizona and Banner University Medical Center in Tucson.<\/p>\n<p>The animal study evaluated the latest iteration of the Emperor TAH, an electromechanically actuated system designed to build upon the established blood-contacting architecture and extensive clinical experience of the SynCardia Total Artificial Heart (\u201cSTAH\u201d) while advancing patient mobility and supporting the future development of a fully implantable artificial heart system.<\/p>\n<p>Initial preclinical data from the first-generation Emperor TAH, completed in late 2025, were subsequently presented at the American College of Cardiology and at the International Society for Heart &amp; Lung Transplantation 2026 conferences. Compared to the previous generation device, the latest iteration incorporates an independent dual motor ventricular system enabling side-specific control of systemic and pulmonary circulation. The system is designed to support physiologic responsiveness while preserving the underlying pumping principles and autoregulatory characteristics of the STAH.<\/p>\n<p>Three acute implant procedures were successfully completed. Across all study procedures, the Emperor TAH demonstrated stable hemodynamic support with observations consistent with physiologic autoregulatory behavior. No device-related intraoperative failures were observed.<\/p>\n<p>\u201cThis animal study demonstrated the Emperor\u2019s capability to provide stable full circulatory support in a large animal model and generated important data supporting continued preclinical and translational development activities,\u201d said Andre Simon, MD-PhD, Vice President of Clinical Affairs.<\/p>\n<p>\u201cThe independent ventricular architecture operated as intended under study conditions,\u201d said Matthew Schuster, Chief Operating Officer of Picard Medical and inventor of the Emperor. \u201cThese studies further validated the design and will support ongoing system optimization and future testing.\u201d<\/p>\n<p>\u201cThese studies mark another important milestone toward our goal of a fully implantable artificial heart,\u201d said Patrick Schnegelsberg, Chief Executive Officer of Picard Medical. \u201cThe Emperor TAH is designed to build on decades of clinical experience from the SynCardia platform, with the goal of improving patient mobility and quality of life.\u201d<\/p>\n<p>The studies were conducted in collaboration with researchers and surgical teams at The University of Arizona and Banner University Medical Center Tucson.<\/p>\n<p>The Emperor TAH is being developed as a fully implantable artificial heart platform intended to provide long-term circulatory support for patients with advanced biventricular heart failure without the need for external pneumatic drivers. The Emperor TAH is currently under development and has not received FDA approval or clearance.<\/p>\n<p>\n        <strong>About Picard Medical and SynCardia<\/strong>\n      <\/p>\n<p>Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (\u201cSynCardia\u201d), the Tucson, Arizona\u2013based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (\u201cSTAH\u201d), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g1Y7eXK_slO4G7xXw5HXcHdB5nOmVkl49jXDlG3HevLpdoaQVgTJCB5OXmyG7nQKFyf3vcR_z9ixwczoTNznm9iu0SQJQ9K3VDKi0hzuTbQ=\" rel=\"nofollow\" target=\"_blank\">www.picardmedical.com<\/a> or review the Company\u2019s filings with the U.S. Securities and Exchange Commission at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8RmwSlGPYwiZMuvqz_druBXibzu-1hAIdHjLNnBdWKbxg_3uEzLz9I0U2QNzZ5L7eqHGykgcgrMX-DcXJGeKIg==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Forward-looking statements can often be identified by words such as \u201ccontinue,\u201d \u201cgoal,\u201d \u201cadvance,\u201d \u201cintended,\u201d and \u201cdesigned to,\u201d and similar expressions, and various or negatives of these words. These statements include, but are not limited to, statements regarding supporting clinical partners, advancing development of our next generation fully implantable total artificial heart platform, and the expected benefits of the Emperor TAH. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company\u2019s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Additional information about the Company, including risk factors that may affect the Company\u2019s business, financial condition, and results of operations, is contained in the Company\u2019s filings with the SEC, including the Company\u2019s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge on the SEC\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YEbsmuWlPUB3ukuJ_6v7eDzDpa9oUYjiocVb5T7EJWz_8QVXGEdwyYMzBHdQneRJbbh5CqEER60TOkWLcIiFBQ==\" rel=\"nofollow\" target=\"_blank\">http:\/\/www.sec.gov<\/a> and on the Company\u2019s investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hNACOGsYvhvl8WtkEjGESe9EOo2ESR1uqFnkQZa2SZp-HqxHalvTf4FJLuHEqBQKmQdOGdHGGpxE1OsRnu2cdGeG-albvGlgfQ5eWzSgUQs=\" rel=\"nofollow\" target=\"_blank\">https:\/\/picardmedical.com\/<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>\n        <u>Investors<br \/><\/u>Eric Ribner<br \/>Managing Director<br \/>LifeSci Advisors LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MsleStpjBvArOx1_DKzO8QJAw6sLllog3hgJdi4D-NkkzK6PaZJSRQ2MJdPml26ydG8EydTVNAztvb0wTYqkSZHAKxrCPX4ofwLM1v1mi3vJk6_aijumUHTgq8yKTC30\" rel=\"nofollow\" target=\"_blank\">eric@lifesciadvisors.com<\/a><\/p>\n<p>Picard Medical, Inc.\/SynCardia Systems, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VvFa6tMr3TBgopCWU2Lv9ygRLDyC3GmJkaBvdQIW-3qXFm1QAjH7en3c8hAwz8b77xFm4FOJp4TjQTwptYDkOY8sUzNlI-jj9ORBSXdgSlc=\" rel=\"nofollow\" target=\"_blank\">IR@picardmedical.com<\/a><\/p>\n<p>\n        <u>General\/Media<br \/><\/u>Brittany Lanza<br \/>blanza@syncardia.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2E1MzczYTctOWJmMS00NjFkLWE5MDktYzZlZGZmMTI2NDRjLTUwMDE1MDk2Ni0yMDI2LTA2LTAyLWVu\/tiny\/Picard-Medical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2014 Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures \u2014\u00a0 \u2014 Advancing second-generation Emperor TAH development toward a fully implantable system \u2014 TUCSON, Ariz., June 02, 2026 (GLOBE NEWSWIRE) &#8212; Picard Medical, Inc. (NYSE American: PMI) (the \u201cCompany\u201d or \u201cPicard Medical\u201d), parent company of SynCardia Systems LLC, maker of the world\u2019s first and only total artificial heart approved by both the U.S. FDA and Health Canada, today announced the successful completion of an acute in vivo implant study series using the Company\u2019s next-generation Emperor Total Artificial Heart (\u201cEmperor TAH\u201d or \u201cEmperor\u201d) Platform at the University of Arizona and Banner University Medical Center in Tucson. The animal study evaluated the latest iteration of the Emperor &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-969338","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2014 Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures \u2014\u00a0 \u2014 Advancing second-generation Emperor TAH development toward a fully implantable system \u2014 TUCSON, Ariz., June 02, 2026 (GLOBE NEWSWIRE) &#8212; Picard Medical, Inc. (NYSE American: PMI) (the \u201cCompany\u201d or \u201cPicard Medical\u201d), parent company of SynCardia Systems LLC, maker of the world\u2019s first and only total artificial heart approved by both the U.S. FDA and Health Canada, today announced the successful completion of an acute in vivo implant study series using the Company\u2019s next-generation Emperor Total Artificial Heart (\u201cEmperor TAH\u201d or \u201cEmperor\u201d) Platform at the University of Arizona and Banner University Medical Center in Tucson. The animal study evaluated the latest iteration of the Emperor &hellip; Continue reading &quot;Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T11:57:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Picard Medical \\\/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies\",\"datePublished\":\"2026-06-02T11:57:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/\"},\"wordCount\":870,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/\",\"name\":\"Picard Medical \\\/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==\",\"datePublished\":\"2026-06-02T11:57:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Picard Medical \\\/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/","og_locale":"en_US","og_type":"article","og_title":"Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies - Market Newsdesk","og_description":"\u2014 Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures \u2014\u00a0 \u2014 Advancing second-generation Emperor TAH development toward a fully implantable system \u2014 TUCSON, Ariz., June 02, 2026 (GLOBE NEWSWIRE) &#8212; Picard Medical, Inc. (NYSE American: PMI) (the \u201cCompany\u201d or \u201cPicard Medical\u201d), parent company of SynCardia Systems LLC, maker of the world\u2019s first and only total artificial heart approved by both the U.S. FDA and Health Canada, today announced the successful completion of an acute in vivo implant study series using the Company\u2019s next-generation Emperor Total Artificial Heart (\u201cEmperor TAH\u201d or \u201cEmperor\u201d) Platform at the University of Arizona and Banner University Medical Center in Tucson. The animal study evaluated the latest iteration of the Emperor &hellip; Continue reading \"Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-02T11:57:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies","datePublished":"2026-06-02T11:57:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/"},"wordCount":870,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/","name":"Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==","datePublished":"2026-06-02T11:57:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyOTAyOSM3NjIxNzU1IzUwMDE1MDk2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/picard-medical-syncardia-advances-emperor-total-artificial-heart-program-with-successful-next-generation-preclinical-implant-studies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Picard Medical \/ SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/969338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=969338"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/969338\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=969338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=969338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=969338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}